We and others previously have demonstrated ERC’s valuable effectiveness in treating autoimmune and inflammatory diseases, including experimental hepatitis by the inhibition of CD4+ conventional T cells [14–16]. This evidence concerns the gene CD4 and hepatitis A virus infection.